New US approval for Takeda’s Alunbrig
The move is based on data showing Alunbrig’s superiority over crizotinib as first-line treatment of metastatic ALK+ NSCLC
Read More
Tag: ALK
NICE final guidance backs Pfizer’s Lorviqua
The drug meets NICE’s criteria to be considered a life-extending treatment
Read More
Expanded EU approval for Takeda’s Alunbrig
The expanded indication provides the around 10,000 people living with ALK+ NSCLC in Europe an additional first-line treatment option
Read More
EU green light for Takeda’s Alunbrig
Takeda’s Alunbrig has been approved in Europe as a treatment for a specific group of lung cancer patients, but access to the drug in the UK remains uncertain.
Read More
Preliminary NICE ‘no’ for Takeda’s Alunbrig
Draft guidelines from the National Institute for Health and Care Excellence do not recommend NHS funding for Takeda’s lung cancer drug Alunbrig.
Read More
Takeda’s Alunbrig shows promise as first-line ALK NSCLC therapy
Takeda’s Alunbrig cut the risk of disease progression or death by more than 50% compared to Pfizer’s Xalkori in adults with ALK+ non-small cell lung cancer.
Read More
Pfizer’s lorlatinib clears first hurdle to UK early access scheme
Pfizer’s lorlatinib has been designated a Promising Innovative Medicine for the treatment of some patients with ALK-positive advanced non-small cell lung cancer.
Read More
NICE backs Roche’s Alecensa
Roche’s Alecensa has won NICE backing as a treatment for a rare type of lung cancer, over-turning a prior decision to reject NHS funding for the drug.
Read More
First-line use of lung cancer drug Zykadia gets NHS nod
Final guidelines have now been published endorsing NHS use of Novartis’ Zykadia as a first line of attack for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), offering patients a new treatment option.
Read More
Roche’s Alecensa wins wider US approval for lung cancer
Roche group Genentech says its application to expand the use of Alecensa to include first-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) has been approved by US regulators.
Read More
Pfizer’s lorlatinib impresses in Phase II lung cancer trial
Pfizer has presented Phase II data showing that its next-generation tyrosine kinase inhibitor lorlatinib exhibited “clinically meaningful activity” against lung tumours and brain metastases.
Read More
Roche’s Alecensa gets green light for early access scheme
UK patients with a rare form of lung cancer will be able to access Roche’s Alecensa without the need for prior chemotherapy before official approval is obtained, following its inclusion in the country’s Early Access to Medicines Scheme.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
